BioCentury | Dec 8, 2014
Company News

NeoGenomics sales and marketing update

...to detect mutations in the Bruton’s tyrosine kinase (BtK) and phospholipase C gamma 2 (phosphatidylinositol-specific; PLCG2...
BioCentury | Aug 28, 2014
Cover Story

Overcoming ibrutinib resistance

...signaling ultimately leads to NF-kB activation through a pathway that involves phospholipase Cg2 (phosphatidylinositol-specific) ( PLCG2...
BioCentury | Jul 10, 2014
Distillery Therapeutics

Indication: Cancer

...and contact information Cancer Chronic lymphocytic leukemia (CLL) Bruton's tyrosine kinase (BTK); phospholipase Cg2 (phosphatidylinositol-specific) (PLCG2...
...drug in five of six patients. In two of six patients, gain-of-function resistance mutations in PLCG2...
BioCentury | Mar 26, 2009
Distillery Therapeutics

Indication: Autoimmune disease

...that targeting PLCG2 could treat RA. In a mouse model of autoimmune arthritis, mice with PLCG2-deficient...
...ability. Ongoing work includes studying other PLCG2-deficient mouse models and screening libraries for small molecule PLCG2...
Items per page:
1 - 4 of 4